Prof Frederik Marmé speaks to ecancer at ASCO 2024 about the final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study, which evaluated atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer.

574 pts were randomly assigned to atezolizumab or placebo with 45.1% receiving pegylated liposomal doxorubicin and 53.7% paclitaxel.

Prof Marmé reports that results showed that the addition of atezolizumab to chemotherapy plus bevacizumab did not significantly improve overall survival or progression-free survival in patients.